Bionano Genomics Expects $10M in Proceeds from Direct Offering

Dow Jones04-05
 

By Denny Jacob

 

Bionano Genomics agreed to the purchase and sale of its common stock.

The San Diego genome analysis solutions provider will purchase and sell about 8.7 million shares and warrants to purchase an equivalent amount of shares at a price of $1.145 per share.

The gross proceeds to the company from the offering are expected to be about $10 million before fees and expenses, which it intends to use for measures including research and development expenses. The offering is expected to close on or about April 8.

 

Write to Denny Jacob at denny.jacob@wsj.com

 

(END) Dow Jones Newswires

April 04, 2024 14:00 ET (18:00 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment